基因改变的性别差异和免疫检查点抑制剂反应在泌尿器膀癌中的性别差异
相关实验视频
Updated: Jul 11, 2026

07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
13.0K
Jean-Pierre Trey Kanumuambidi1, Reynier Rodriguez Rosales1, Arjun Venkatesh1
1Department of Urology, University of Florida College of Medicine, Jacksonville, FL.
Urologic oncology
|June 7, 2025
概括
膀癌的体质遗传改变显示出性别特异的模式,影响生存和免疫反应. RB1和AR变化是不良结果的关键驱动因素,需要针对性别的治疗策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 膀癌在发病率,攻击性和生存率方面显示出明显的基于性别的差异.
- 男性的发病率更高,而女性往往经历较差的结果.
研究的目的:
- 调查尿道膀癌中性别特异的体质遗传变化.
- 分析这些改变对患者生存,免疫细胞透和对免疫检查点抑制剂 (ICI) 的反应的影响.
主要方法:
- 分析了来自3,157名尿道膀癌患者的下一代测序数据 (AACR项目GENIE).
- 卡普兰-梅尔总生存分析,TIMER2.0和ROC Plotter用于免疫分析和ICI反应评估.
- 合成致命相互作用和基因共发生模式的识别.
主要成果:
- 身体基因变异发生在男性 (38%) 比女性 (29%) 更频繁.
- 在男性中,RB1,CDKN1A和ERCC2的变化更为常见,并且与明显更差的生存率有关.
- 在女性中,AR基因变异更频繁,并且与单细胞透率的降低有关,而RB1变异增加了CD8+ T细胞和NK细胞透率.
结论:
- 身体基因变异在膀癌中显著导致基于性别的生存差异.
- RB1和AR变化是不良结果和潜在治疗点的关键驱动因素.
- 研究结果强调在膀癌管理中需要针对性别量身定制的治疗策略.
更多相关视频
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Nursing Assessment of the Genitourinary System I: Health History
The genitourinary system is critical to maintaining fluid balance, waste elimination, and reproductive function. Nurses play a vital role in assessing this system, beginning with a thorough health history. This process involves gathering patient information, identifying risk factors, and recognizing symptoms of genitourinary disorders. Early detection is vital for timely interventions and management.1. Gathering Patient InformationA complete health history includes the patient’s personal,...

